Long-term treatment with human growth hormone, also known as somatropin, does not seem to influence mortality in people with Prader-Willi syndrome (PWS), but may increase the risk of developing type 2 diabetes, a study from South Korea found. The risk of type 2 diabetes increased by 6%…
Read more
Prader-Willi syndrome (PWS) is associated with shorter life expectancy, impaired quality of life, and high healthcare and caregiving costs — all of which place a heavy burden on families and the healthcare system. That’s according to a systematic review of more than 130 published studies. Data also found that…
Once-daily treatment with pitolisant is generally safe and helps reduce excessive daytime sleepiness (EDS) and abnormal behaviors in people with Prader-Willi syndrome (PWS) — notably with the repurposed therapy given at higher doses, and especially in children. That’s according to the full results of a proof-of-concept trial that tested two…
Prader-Will syndrome is a rare and complex genetic condition that results in a variety of physical and mental symptoms. Learn more about the disease here.
Prader-Willi is caused by genetic changes in a particular area of chromosome 15. Learn more about what causes the disease here.
Symptoms of Prader-Willi range from physical impairments to cognitive and behavioral issues. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
